The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade
Immunotherapy has revolutionized treatment of cancer during the last decades. Oncolytic virotherapy has also emerged as a strategy to fight against cancer cells both via lysis of malignant cells and activating immune responses. Accepted as a logical strategy, combination of monoclonal antibodies par...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-05-01
|
| Series: | Biomedicine & Pharmacotherapy |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S075333222300224X |
| _version_ | 1797857787545387008 |
|---|---|
| author | Sajad Najafi Jamal Majidpoor Keywan Mortezaee |
| author_facet | Sajad Najafi Jamal Majidpoor Keywan Mortezaee |
| author_sort | Sajad Najafi |
| collection | DOAJ |
| description | Immunotherapy has revolutionized treatment of cancer during the last decades. Oncolytic virotherapy has also emerged as a strategy to fight against cancer cells both via lysis of malignant cells and activating immune responses. Accepted as a logical strategy, combination of monoclonal antibodies particularly against the programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) is introduced to improve clinical responses to immune checkpoint inhibitors (ICIs). Accordingly, Talimogene laherparepvec (T-VEC) has received approval for clinical use, while a number of oncolytic Adenoviruses (Ads) are being investigated in clinical trials of malignancies. Combination of oncolytic Ads with PD-1/PD-L1 inhibitors have shown potentials in promoting responses to ICIs, changing the tumor microenvironment, inducing long-term protection against tumor, and promoting survival among mice models of malignancies. Regarding the increasing importance of oncolytic Ads in combination therapy of cancers, in this review we decide to outline recent studies in this field. |
| first_indexed | 2024-04-09T21:02:27Z |
| format | Article |
| id | doaj.art-efe1223912ea4102928f57d49a6e4b3c |
| institution | Directory Open Access Journal |
| issn | 0753-3322 |
| language | English |
| last_indexed | 2024-04-09T21:02:27Z |
| publishDate | 2023-05-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Biomedicine & Pharmacotherapy |
| spelling | doaj.art-efe1223912ea4102928f57d49a6e4b3c2023-03-29T09:21:28ZengElsevierBiomedicine & Pharmacotherapy0753-33222023-05-01161114436The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockadeSajad Najafi0Jamal Majidpoor1Keywan Mortezaee2Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Cellular and Molecular Biology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IranDepartment of Anatomy, School of Medicine, Infectious Diseases Research Center, Gonabad University of Medical Sciences, Gonabad, IranDepartment of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran; Cancer and Immunology Research Center, Research Institute for Health Development, Kurdistan University of Medical Sciences, Sanandaj, Iran; Corresponding author at: Department of Anatomy, School of Medicine, Kurdistan University of Medical Sciences, Sanandaj, Iran.Immunotherapy has revolutionized treatment of cancer during the last decades. Oncolytic virotherapy has also emerged as a strategy to fight against cancer cells both via lysis of malignant cells and activating immune responses. Accepted as a logical strategy, combination of monoclonal antibodies particularly against the programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) is introduced to improve clinical responses to immune checkpoint inhibitors (ICIs). Accordingly, Talimogene laherparepvec (T-VEC) has received approval for clinical use, while a number of oncolytic Adenoviruses (Ads) are being investigated in clinical trials of malignancies. Combination of oncolytic Ads with PD-1/PD-L1 inhibitors have shown potentials in promoting responses to ICIs, changing the tumor microenvironment, inducing long-term protection against tumor, and promoting survival among mice models of malignancies. Regarding the increasing importance of oncolytic Ads in combination therapy of cancers, in this review we decide to outline recent studies in this field.http://www.sciencedirect.com/science/article/pii/S075333222300224XProgrammed death-1 (PD-1)Programmed death-ligand 1 (PD-L1)Adenovirus (Ad)ImmunotherapyImmune checkpoint inhibitor (ICI) |
| spellingShingle | Sajad Najafi Jamal Majidpoor Keywan Mortezaee The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade Biomedicine & Pharmacotherapy Programmed death-1 (PD-1) Programmed death-ligand 1 (PD-L1) Adenovirus (Ad) Immunotherapy Immune checkpoint inhibitor (ICI) |
| title | The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade |
| title_full | The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade |
| title_fullStr | The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade |
| title_full_unstemmed | The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade |
| title_short | The impact of oncolytic adenoviral therapy on the therapeutic efficacy of PD-1/PD-L1 blockade |
| title_sort | impact of oncolytic adenoviral therapy on the therapeutic efficacy of pd 1 pd l1 blockade |
| topic | Programmed death-1 (PD-1) Programmed death-ligand 1 (PD-L1) Adenovirus (Ad) Immunotherapy Immune checkpoint inhibitor (ICI) |
| url | http://www.sciencedirect.com/science/article/pii/S075333222300224X |
| work_keys_str_mv | AT sajadnajafi theimpactofoncolyticadenoviraltherapyonthetherapeuticefficacyofpd1pdl1blockade AT jamalmajidpoor theimpactofoncolyticadenoviraltherapyonthetherapeuticefficacyofpd1pdl1blockade AT keywanmortezaee theimpactofoncolyticadenoviraltherapyonthetherapeuticefficacyofpd1pdl1blockade AT sajadnajafi impactofoncolyticadenoviraltherapyonthetherapeuticefficacyofpd1pdl1blockade AT jamalmajidpoor impactofoncolyticadenoviraltherapyonthetherapeuticefficacyofpd1pdl1blockade AT keywanmortezaee impactofoncolyticadenoviraltherapyonthetherapeuticefficacyofpd1pdl1blockade |